Biblio
Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.
. Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer. 2024:e30892.
. Secondary impact of the COVID-19 pandemic on patients and the cell therapy healthcare ecosystem. Transplant Cell Ther. 2022.
Reduced Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplant: Gonadal Toxicity and Fertility Following Pediatric HSC. Transplant Cell Ther. 2022.
Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Quality Improvement Initiative to Reduce Nighttime Noise in a Transplantation and Cellular Therapy Unit. Biol Blood Marrow Transplant. 2019.
A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Blood. 2023.
. Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. Transplant Cell Ther. 2021.
Pediatric Transplant Associated Thrombotic Microangiopathy Healthcare Utilization and Implications of Eculizumab Therapy. Blood Adv. 2023.
. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis. 2019.
Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma. Haematologica. 2023.
Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166-1177.
. Increased body mass index augments endothelial injury and clinical outcomes after hematopoietic stem cell transplant: Higher BMI increases endothelial injury after BMT. Transplant Cell Ther. 2023.
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
Incidence of bloodstream infections after hematopoietic stem cell transplant for Hurler Syndrome. Transplant Cell Ther. 2023.
. Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. Biol Blood Marrow Transplant. 2019.
. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Feasibility of continuous temperature monitoring in pediatric immunocompromised patients: A pilot study. Pediatr Blood Cancer. 2019:e27723.
. Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022.
. Daytime-restricted parenteral feeding is associated with earlier oral intake in children following stem cell transplant. J Clin Invest. 2023;133(4).
. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Haematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022.
. Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2018.